Ivan O Rosas1, Hilary J Goldberg1, Harold R Collard2, Souheil El-Chemaly1, Kevin Flaherty3, Gary M Hunninghake1, Joseph A Lasky4, David J Lederer5, Roberto Machado6, Fernando J Martinez7, Rie Maurer8, Danielle Teller1, Imre Noth9, Elizabeth Peters7, Ganesh Raghu10, Joe G N Garcia11, Augustine M K Choi12. 1. Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. 2. Division of Pulmonary and Critical Care Medicine, University of California San Francisco, San Francisco, CA. 3. Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI. 4. Pulmonary and Critical Care Medicine Section, Tulane University Medical School, New Orleans, LA. 5. Division of Pulmonary and Critical Care Medicine, Columbia University Medical Center, New York, NY. 6. Division of Pulmonary and Critical Care Medicine, University of Illinois at Chicago, Chicago, IL. 7. Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medical College, New York, NY. 8. The Harvard Clinical and Translational Science Center, Boston, MA. 9. Division of Pulmonary and Critical Care Medicine, University of Chicago, Chicago, IL. 10. Division of Pulmonary and Critical Care Medicine, University of Washington Medical Center, Seattle, WA. 11. Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, University of Arizona College of Medicine, Tucson, AZ. 12. Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medical College, New York, NY. Electronic address: amc2056@med.cornell.edu.
Abstract
BACKGROUND: Preclinical studies have demonstrated that low-dose carbon monoxide (CO) can abrogate experimental lung fibrosis. To test the therapeutic role of inhaled CO, we designed a clinical study in patients with idiopathic pulmonary fibrosis (IPF). METHODS: We conducted a multicenter, phase IIa, double-blinded, sham-controlled, clinical trial. Patients with IPF were randomized to treatment with inhaled CO at 100 to 200 parts per million or to inhaled 21% oxygen for 2 h daily, twice weekly, for 12 weeks. The primary study end point was the difference in change in matrix metalloproteinase-7 (MMP7) serum concentration after 12 weeks of treatment. Secondary end points included pulmonary function test measures, 6-min walk distance, rates of adverse events, acute exacerbation, hospitalization and death, and quality of life measures. RESULTS:Fifty-eight subjects were randomized to treatment with inhaled CO (n = 29) or placebo (n = 29). Despite modest increases in CO blood levels, the change in MMP7 concentrations after 12 weeks of treatment did not significantly differ between the study arms (MMP7 difference at week 12, -0.90 ng/mL; 95% CI, -4.18 to 2.38 ng/mL). No differences were observed in physiologic measures, incidence of acute exacerbations, hospitalization, death, or patient-reported outcomes. Importantly, no differences in distribution of adverse events were noted between the treatment arms. CONCLUSIONS:Inhaled CO is well tolerated and can be safely administered to patients with IPF in the ambulatory setting; however, inhaled CO did not result in significant changes in study end points. Our findings support testing the efficacy of inhaled therapies in future IPF clinical trials. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT01214187; URL: www.clinicaltrials.gov.
RCT Entities:
BACKGROUND: Preclinical studies have demonstrated that low-dose carbon monoxide (CO) can abrogate experimental lung fibrosis. To test the therapeutic role of inhaled CO, we designed a clinical study in patients with idiopathic pulmonary fibrosis (IPF). METHODS: We conducted a multicenter, phase IIa, double-blinded, sham-controlled, clinical trial. Patients with IPF were randomized to treatment with inhaled CO at 100 to 200 parts per million or to inhaled 21% oxygen for 2 h daily, twice weekly, for 12 weeks. The primary study end point was the difference in change in matrix metalloproteinase-7 (MMP7) serum concentration after 12 weeks of treatment. Secondary end points included pulmonary function test measures, 6-min walk distance, rates of adverse events, acute exacerbation, hospitalization and death, and quality of life measures. RESULTS: Fifty-eight subjects were randomized to treatment with inhaled CO (n = 29) or placebo (n = 29). Despite modest increases in CO blood levels, the change in MMP7 concentrations after 12 weeks of treatment did not significantly differ between the study arms (MMP7 difference at week 12, -0.90 ng/mL; 95% CI, -4.18 to 2.38 ng/mL). No differences were observed in physiologic measures, incidence of acute exacerbations, hospitalization, death, or patient-reported outcomes. Importantly, no differences in distribution of adverse events were noted between the treatment arms. CONCLUSIONS: Inhaled CO is well tolerated and can be safely administered to patients with IPF in the ambulatory setting; however, inhaled CO did not result in significant changes in study end points. Our findings support testing the efficacy of inhaled therapies in future IPF clinical trials. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT01214187; URL: www.clinicaltrials.gov.
Authors: Thomas J Richards; Naftali Kaminski; Fred Baribaud; Susan Flavin; Carrie Brodmerkel; Daniel Horowitz; Katherine Li; Jiin Choi; Louis J Vuga; Kathleen O Lindell; Melinda Klesen; Yingze Zhang; Kevin F Gibson Journal: Am J Respir Crit Care Med Date: 2012-01-01 Impact factor: 21.405
Authors: Zhihong Zhou; Ruiping Song; Cheryl L Fattman; Sara Greenhill; Sean Alber; Tim D Oury; Augustine M K Choi; Danielle Morse Journal: Am J Pathol Date: 2005-01 Impact factor: 4.307
Authors: E Bathoorn; D-J Slebos; D S Postma; G H Koeter; A J M van Oosterhout; M van der Toorn; H M Boezen; H A M Kerstjens Journal: Eur Respir J Date: 2007-08-22 Impact factor: 16.671
Authors: Amy L Olson; Jeffrey J Swigris; Dennis C Lezotte; Jill M Norris; Carla G Wilson; Kevin K Brown Journal: Am J Respir Crit Care Med Date: 2007-05-03 Impact factor: 21.405
Authors: Talmadge E King; Williamson Z Bradford; Socorro Castro-Bernardini; Elizabeth A Fagan; Ian Glaspole; Marilyn K Glassberg; Eduard Gorina; Peter M Hopkins; David Kardatzke; Lisa Lancaster; David J Lederer; Steven D Nathan; Carlos A Pereira; Steven A Sahn; Robert Sussman; Jeffrey J Swigris; Paul W Noble Journal: N Engl J Med Date: 2014-05-18 Impact factor: 91.245
Authors: Ivan O Rosas; Thomas J Richards; Kazuhisa Konishi; Yingze Zhang; Kevin Gibson; Anna E Lokshin; Kathleen O Lindell; Jose Cisneros; Sandra D Macdonald; Annie Pardo; Frank Sciurba; James Dauber; Moises Selman; Bernadette R Gochuico; Naftali Kaminski Journal: PLoS Med Date: 2008-04-29 Impact factor: 11.069
Authors: Laura E Fredenburgh; Mark A Perrella; Diana Barragan-Bradford; Dean R Hess; Elizabeth Peters; Karen E Welty-Wolf; Bryan D Kraft; R Scott Harris; Rie Maurer; Kiichi Nakahira; Clara Oromendia; John D Davies; Angelica Higuera; Kristen T Schiffer; Joshua A Englert; Paul B Dieffenbach; David A Berlin; Susan Lagambina; Mark Bouthot; Andrew I Sullivan; Paul F Nuccio; Mamary T Kone; Mona J Malik; Maria Angelica Pabon Porras; Eli Finkelsztein; Tilo Winkler; Shelley Hurwitz; Charles N Serhan; Claude A Piantadosi; Rebecca M Baron; B Taylor Thompson; Augustine Mk Choi Journal: JCI Insight Date: 2018-12-06
Authors: Isha H Jain; Luca Zazzeron; Olga Goldberger; Eizo Marutani; Gregory R Wojtkiewicz; Tslil Ast; Hong Wang; Grigorij Schleifer; Anna Stepanova; Kathleen Brepoels; Luc Schoonjans; Peter Carmeliet; Alexander Galkin; Fumito Ichinose; Warren M Zapol; Vamsi K Mootha Journal: Cell Metab Date: 2019-08-08 Impact factor: 27.287
Authors: John A McClung; Lior Levy; Victor Garcia; David E Stec; Stephen J Peterson; Nader G Abraham Journal: Pharmacol Ther Date: 2021-09-06 Impact factor: 12.310
Authors: James D Byrne; David Gallo; Hannah Boyce; Sarah L Becker; Kristi M Kezar; Alicia T Cotoia; Vivian R Feig; Aaron Lopes; Eva Csizmadia; Maria Serena Longhi; Jung Seung Lee; Hyunjoon Kim; Adam J Wentworth; Sidharth Shankar; Ghee Rye Lee; Jianling Bi; Emily Witt; Keiko Ishida; Alison Hayward; Johannes L P Kuosmanen; Josh Jenkins; Jacob Wainer; Aya Aragon; Kaitlyn Wong; Christoph Steiger; William R Jeck; Dustin E Bosch; Mitchell C Coleman; Douglas R Spitz; Michael Tift; Robert Langer; Leo E Otterbein; Giovanni Traverso Journal: Sci Transl Med Date: 2022-06-29 Impact factor: 19.319